Efficacy and safety of ormeloxifene in management of menorrhagia: A pilot study

Kriplani, Alka; Kulshrestha, Vidushi; Agarwal, Nutan

doi:10.1111/j.1447-0756.2008.00987.x

Cited by 46 publications

(63 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, we analysed the efficacy of Ormeloxifene in patients with DUB and our results suggested significant reduction in Mean PBAC score from 316 to 52 (p<0.005) which was comparable with the studies conducted by Kriplani et al and Dadich et al 10,11 There was a significant rise in mean haemoglobin concentration from 8.4 to 9.8g/dl after six months of treatment with a rise of 1.4g/dl. The mean endometrial thickness decreased from 10.8mm to 8.1 mm with 6 months therapy of ormeloxifene and this decrease was found to be statistically significant.…”

Section: Discussionsupporting

confidence: 76%

The role of Sevista (ormeloxifene) in the management of dysfunctional uterine bleeding

Gandotra¹,

Sharma²,

Sharma

et al. 2016

Int J Reprod Contracept Obstet Gynecol

View full text Add to dashboard Cite

Background: Dysfunctional uterine bleeding (DUB) is a common gynaecological disorder that usually ends up in hysterectomy and causes psychological and physiological stress. Medical management with hormones and NSAIDS has inherited side effects. Ormeloxifene, a selective estrogen receptor modulator, is emerging as a safe and effective agent for dysfunctional uterine bleeding. The objective of the study was to evaluate the role of ormeloxifene in medical management of dysfunctional uterine bleeding.Methods: 30 patients, on whom diagnosis of dysfunctional uterine bleeding was made, were included in the study. Patients were given ormeloxifene 60mg twice a week for 12 weeks and then once a week for 12 weeks. The primary outcome measures were menstrual blood loss (assessed by pictorial blood assessment chart score), hemoglobin concentration and endometrial thickness. The secondary outcome measures were acceptability and side effects of ormeloxifene.Results: There was a significant reduction in mean PBAC score from 316 to 52 after six months of treatment. The mean hemoglobin concentration increased significantly from 8.4 to 9.8 gms/dl with a rise of 1.4gm/dl (p <0.05). The mean pretreatment endometrial thickness was 10.8mm and it decreased significantly to 8.1mm after 6 months of treatment with ormeloxifene (p < 0.05). 76.7% of the women showed marked subjective improvement in symptoms. The most common side effect reported was amenorrhea (13.3%).Conclusions: Ormeloxifene can be considered as an effective and safe therapeutic option for the medical management of dysfunctional uterine bleeding.

show abstract

Section: Discussionsupporting

confidence: 76%

The role of Sevista (ormeloxifene) in the management of dysfunctional uterine bleeding

Gandotra¹,

Sharma²,

Sharma

et al. 2016

Int J Reprod Contracept Obstet Gynecol

View full text Add to dashboard Cite

show abstract

“…Ormeloxifene is a good alternative to save the patient from hysterectomy. Twice weekly schedule, low cost, minimal side effects, and reducing up to 70 % blood loss with faster response all these facts make ormeloxifene a good option in medical management of AUB [5]. The results of this study are comparable to other studies also.…”

Section: Discussionsupporting

confidence: 74%

“…The reason might be that their pre-treatment endometrial thickness was also higher than our study. In a study by Kriplani et al [5], the mean hemoglobin was increased to 11.2 g % from 10.6 g %, while Komaram et al [9] found an increment in hemoglobin from 9.2 to 10.5 g %. These results are similar to that of our study.…”

Section: Discussionmentioning

confidence: 99%

“…It is also known as centchroman, a nonsteroidal, selective estrogen receptor modulator (SERM), with potent estrogen antagonistic action on uterus as well as breast tissue and mild agonistic action on bone mineral density [3,4]. It is very effective, reducing up to 70 % blood loss with minimal side effects, has an easy dosing schedule, and cost efficient [5].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Comparative Study of Ormeloxifene and Medroxyprogesterone Acetate in Abnormal Uterine Bleeding

Godha

Mohsin²,

Hakim³

et al. 2015

J Obstet Gynecol India

View full text Add to dashboard Cite

About the Author AbstractPurpose The purpose of this study was to compare the effects of ormeloxifene with medroxyprogesterone acetate in patients with abnormal uterine bleeding. Material and Method 440 Patients were divided into two groups. In group A, ormeloxifene was given at the dosage of 60 mg twice a week for 3 months followed by 60 mg once a week for 1 month. In group B, medroxyprogesterone acetate was given at the dosage of 10 mg twice a day from day 5 to day 25 of the menstrual cycle. At followups, patients were assessed for PBAC score, endometrial thickness by USG, hemoglobin level, and the side effects of drug therapy. Results There were 240 patients in group A and 200 in group B. Reduction in median PBAC score was 79.4 % in group A and 75 % in group B after 4 months of treatment. The mean duration of bleeding reduced to 4.8 from 9 in group A and 5 from 8.7 in group B. Mean hemoglobin was increased from 8.6 to 9.8 g % in group A and from 8.7 to 9.9 g % in group B; endometrial thickness was reduced 123 from 7.7 mm to 6.8 mm in group A and from 7.4 mm to 6.9 mm in group B.Conclusion We conclude from this study that ormeloxifene should be considered the first choice in the management of AUB, especially in the perimenopausal age group where amenorrhea is acceptable.

show abstract

“…However, Kriplani et al 14 found secretory endometrium to be the most common pattern followed by proliferative and simple hyperplasia without atypia.…”

Section: Discussionmentioning

confidence: 99%

Comparative evaluation of the efficacy and safety of ormeloxifene and norethisterone in dysfunctional uterine bleeding

Agarwal

Singh

et al. 2013

Int J Reprod Contracept Obstet Gynecol

View full text Add to dashboard Cite

Background: Dysfunctional Uterine Bleeding (DUB) is the most common cause of abnormal uterine bleeding and is a major indication for referral to gynecological clinics. There are very few studies comparing the effect of ormeloxifene and progesterone in DUB. The objective of the study was to assess the efficacy and safety of Ormeloxifene in DUB and compare it with Norethisterone. Methods: Hundred women presenting with DUB were randomly allocated to 2 equal groups, Group-A, which received 60mg ormeloxifene twice a week for 12 weeks followed by 60mg once a week for next 12 weeks and Group-B, which received 5mg norethisterone twice daily for 21 days for 6 cycles. The primary outcomes were reduction in menstrual blood loss [measured by fall in PBAC (Pictorial Blood loss Assessment Chart) score and subjective assessment], rise in hemoglobin level and decrease in endometrial thickness. Results: The reduction in mean PBAC score with ormeloxifene (216 to 88) was significantly more than with norethisterone (262 to 162) at 3 months (p<0.01). The rise in hemoglobin concentration and fall in endometrial thickness were also significantly more with ormeloxifene than norethisterone (7.52g% to 9.2g% vs. 7.48g% to 8.4g%, p<0.05, and 12.12mm to 9.46mm vs. 12.05mm to 10.7mm, p<0.05, respectively). Further improvement at 6 months was much more with ormeloxifene. No major side effects were reported in any group. Conclusions: Both drugs are effective in treating DUB, but ormeloxifene is superior to norethisterone in reducing menstrual blood loss. [Int J Reprod Contracept Obstet Gynecol 2013; 2(2.000): 194-198

show abstract

Efficacy and safety of ormeloxifene in management of menorrhagia: A pilot study

Abstract: Ormeloxifene is an effective and safe therapeutic option for the medical management of menorrhagia.

Cited by 46 publications

References 28 publications

The role of Sevista (ormeloxifene) in the management of dysfunctional uterine bleeding

The role of Sevista (ormeloxifene) in the management of dysfunctional uterine bleeding

Comparative Study of Ormeloxifene and Medroxyprogesterone Acetate in Abnormal Uterine Bleeding

Comparative evaluation of the efficacy and safety of ormeloxifene and norethisterone in dysfunctional uterine bleeding

Contact Info

Product

Resources

About